美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Torsemide [5 mg, 10 mg, 20 mg and 100 mg]	Tablet	II (Paddle)	50	0.1 N HCl	900	5, 10, 15 and 30	2004/02/20
Tovorafenib	Tablet	II (Paddle)	65	0.1 N HCl with 0.25% SDS	900	5, 10, 15, 20, 30, 45 and 60	2026/01/28
Tovorafenib	For suspension	II (Paddle)	50	0.1 N HCl with 0.3% SDS	900	5, 10, 15, 20, 30, 45 and 60	2026/01/28
Tradipitant	Capsule	II (Paddle) with sinker	75	0.01 N HCl with 0.2% SDS	1000	5, 10, 15, 20, 30, 45 and 60	2026/03/25
Tramadol	Capsule (Extended Release)			Develop a dissolution method			2023/09/15
Tramadol HCl	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Tramadol HCl	Tablet (Extended Release)	I (Basket)	75	0.1 N HCl	900	2, 4, 8, 10 and 16 hours	2007/01/03
Trametinib Dimethyl Sulfoxide	Tablet	II (Paddle)	60	pH 4.5, 50 mM Sodium Acetate with 0.75% Sodium Lauryl Sulfate [SLS]	500	5, 10, 15, 20 and 30	2015/12/24
Trandolapril	Tablet			Develop a dissolution method			2023/09/15
Trandolapril/Verapamil HCl	Tablet (Extended Release)	II (Paddle)	50	Trandolapril: Develop a dissolution method; Verapamil: 0-1 hour Gastric Fluid w/o Pepsin pH=1.2, 1-8 hour Intestinal Fluid w/o Pancreatin	Verapamil: 900	Verapamil: 1, 2, 3.5, 5 and 8 hours	2023/09/15
Tranexamic Acid	Tablet			Develop a dissolution method			2023/09/15
Tranylcypromine Sulfate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Travoprost	Implant			Develop a method to characterize in vitro release			2026/01/28
Trazodone HCl	Tablet			Refer to USP			2023/05/18
Trazodone HCl	Tablet (Extended Release)			Develop a dissolution method			2023/09/15
Treprostinil Diolamine	Tablet (Extended Release)	I (Basket)	100	0.05 M Phosphate Buffer, pH 6.8 (deaerated)	500	1, 2, 4, 6, 8, 12, 16, 20 and 24 hours	2016/06/02
Tretinoin	Capsule	I (Basket)	100	0.5% solid Lauryldimethylamine-oxide (LDAO) in 0.05M Phosphate Buffer, pH 7.8	900	10, 15, 20, 30 and 45	2010/08/05
Triamcinolone Acetonide	Injectable Suspension			Develop a dissolution method using USP IV (Flow-Through Cell), and, if applicable, Apparatus II (Paddle) or any other appropriate method, for comparative evaluation by the Agency			2010/01/15
Triamcinolone Acetonide	Intra-Articular, For Suspension (Extended Release)	II (Paddle)	75	0.3% SDS in 10 mM phosphate buffer, pH 7.2 + 0.02% sodium azide @35°C	1000	1, 2, 4, 8, 12, 16, 24, 36, 48, 72, 96 and 120 hours	2018/02/08
Triclabendazole	Tablet	II (Paddle)	75	0.1N HCl with 1% Tween 20	1000	5, 10, 15, 20 and 30	2020/08/27